APA (7th ed.) Citation

AM, B., J, E., K, P., S, K., E, T., S, S., . . . AH, W. (2024). Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. American journal of hematology, 99(2), E32. https://doi.org/10.1002/ajh.27161

Chicago Style (17th ed.) Citation

AM, Brunner, et al. "Phase Ib Study of Sabatolimab (MBG453), a Novel Immunotherapy Targeting TIM-3 Antibody, in Combination with Decitabine or Azacitidine in High- or Very High-risk Myelodysplastic Syndromes." American Journal of Hematology 99, no. 2 (2024): E32. https://doi.org/10.1002/ajh.27161.

MLA (9th ed.) Citation

AM, Brunner, et al. "Phase Ib Study of Sabatolimab (MBG453), a Novel Immunotherapy Targeting TIM-3 Antibody, in Combination with Decitabine or Azacitidine in High- or Very High-risk Myelodysplastic Syndromes." American Journal of Hematology, vol. 99, no. 2, 2024, p. E32, https://doi.org/10.1002/ajh.27161.